Keeping it in the family: HER3 as a target in brain metastases.
Sheheryar K KabrajiNancy U LinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In 180 patients with metastatic breast cancer and NSCLC, HER3 expression was found in >70% of brain metastases (BM). HER3-targeting antibody-drug conjugates have demonstrated efficacy in HER3-expressing metastatic breast cancer and NSCLC. Thus, HER3 expression by IHC may be a biomarker for development of HER3-targeting BM-specific therapeutics.